-

STAAR Surgical to Report Third Quarter Results on October 30, 2024

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the third quarter ended September 27, 2024, on Wednesday, October 30, 2024, after the market close.

Event: STAAR Surgical 3Q 2024 Financial Results Webcast
Date: Wednesday, October 30, 2024
Time: 4:30 p.m. ET / 1:30 p.m. PT
Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=fmU0YbKB

STAAR will also host an earnings webcast on Wednesday, October 30 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. The live webcast, including an option to pre-register, can be accessed using the preceding link or the “Investors” section of the STAAR website at https://investors.staar.com/

A replay of the webcast will be available on October 30, 2024, at approximately 8:00 p.m. Eastern at the preceding link for at least 90 days.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com

Contacts

Investors & Media
Brian Moore
Vice President, Investor Relations and Corporate Development
(626) 303-7902, Ext. 3023
bmoore@staar.com

Investors – Asia
Niko Liu, CFA
Director, Investor Relations and Corporate Development – Asia
+852-6092-5076
nliu@staar.com

STAAR Surgical Company

NASDAQ:STAA

Release Versions

Contacts

Investors & Media
Brian Moore
Vice President, Investor Relations and Corporate Development
(626) 303-7902, Ext. 3023
bmoore@staar.com

Investors – Asia
Niko Liu, CFA
Director, Investor Relations and Corporate Development – Asia
+852-6092-5076
nliu@staar.com

More News From STAAR Surgical Company

STAAR Surgical Reports Second Quarter 2026 Results

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended July 3, 2026. Second Quarter 2026 Financial Overview Net sales of $93.5 million, up 111% Y/Y Net sales excluding China of $41.2 million, up 6.0% Y/Y China sales of $52.3 million up over 100%, 10% sequentially APAC sales up 189% Y/Y, ex-China sales up...

STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that following an extensive global search, its Board of Directors (the "Board") has appointed Warren Foust as President and Chief Executive Officer and a new member of the Board of Directors, effective August 4, 2026. Mr. Foust joined STAAR in April 2023 and h...

STAAR Surgical to Host Second Quarter 2026 Earnings Results Call and Webcast on August 12, 2026

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results in combination with a shareholder letter for the second quarter ended July 3, 2026, on Wednesday, August 12, 2026, after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and...
Back to Newsroom